Guggenheim raised the firm’s price target on Adagene (ADAG) to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for FY25 earnings, the ATM offering, and modest adjustments to its assumptions for lead asset muzastotug.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene 18.666M share Spot Secondary priced at $3.75
- Adagene enters pact with Incyte for combination of muzastotug, INCA33890
- Adagene announces results from the latest data cut of muzastotug study
- Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer
- Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline